All in all, our comprehensive analysis demonstrates that SHROOM4 is significantly downregulated in NSCLC and is associated with clinical outcomes, genetic alterations, immune infiltration, angiogenesis, stromal cells and extracellular matrix. This evidence concerns the gene SHROOM4 and non-small cell lung carcinoma.